The Phase I clinical trial in China is a single-center, randomized, double-blind, placebo-controlled, dose-exploring clinical trial, which aims to evaluate the safety and resistance of pGX9501 through ID and subsequent EP administration using CELLECTRA® 2000 equipment. Receptivity and immunogenicity, the subjects are healthy adults aged 18 to 59 years old in China.